Foundational therapy for heart failure and a reduced ejection fraction consists of a
combination of an angiotensin receptor–neprilysin inhibitor, a beta‐blocker, a …

Background: Heart failure with improved ejection fraction (HFimpEF) is classified as a new
type of heart failure, and its prevalence and prognosis are not consistent in previous studies …

Methods The data of Korean National Health Insurance big data, the Korean Heart Failure
(KorHF) and the Korean Acute Heart Failure (KorAHF) registries have been used. Results In …

Background Many patients with heart failure (HF) experience changes in left ventricular
ejection fraction (LVEF) during follow‐up. We sought to evaluate the predictors and …

Left ventricular (LV) systolic dysfunction represents a highly treatable cause of heart failure
(HF). A substantial proportion of patients with HF with reduced ejection fraction (EF; HFrEF) …

There is limited data on whether diastolic dysfunction in patients with heart failure (HF) and
recovered ejection fraction (HFrecEF) is associated with worse prognosis. We …

Consenso de expertos sobre la insuficiencia cardiaca con fracción de eyección reducida:
más allá de las guías | Rev. esp. cardiol. Supl. (Ed. impresa);20(supl.B): 1-46, abr. 2020. ilus …

Heart failure with improved ejection fraction (HFimpEF) has better outcomes than HF with
reduced EF (HFrEF). However, factors contributing to HFimpEF remain unclear. This study …

Background Withdrawal of optimal medical therapy has been reported to relapse cardiac
dysfunction in patients with dilated cardiomyopathy (DCM) whose cardiac function had …

Abstract Background The prospective WEARIT-II-EUROPE registry aimed to assess the
value of the wearable cardioverter-defibrillator (WCD) prior to potential ICD implantation in …